{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T02:12:32Z","timestamp":1781835152503,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1038\/eye.2016.126","type":"journal-article","created":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T13:04:53Z","timestamp":1467378293000},"page":"1343-1350","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Ocular hypotensive effect of fixed-combination brinzolamide\/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial"],"prefix":"10.1038","volume":"30","author":[{"given":"R D","family":"Fechtner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J S","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D A","family":"Hubatsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D L","family":"Budenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H B","family":"DuBiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,1]]},"reference":[{"key":"BFeye2016126_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1177\/112067210801800517","volume":"18","author":"WC Stewart","year":"2008","unstructured":"Stewart WC, Kolker AE, Sharpe ED, Day DG, Konstas AG, Hollo G et al. Long-term progression at individual mean intraocular pressure levels in primary open-angle and exfoliative glaucoma. Eur J Ophthalmol 2008; 18: 765\u2013770.","journal-title":"Eur J Ophthalmol"},{"key":"BFeye2016126_CR2","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/aos.12203","volume":"92","author":"D Peters","year":"2014","unstructured":"Peters D, Bengtsson B, Heijl A . Factors associated with lifetime risk of open-angle glaucoma blindness. Acta Ophthalmol 2014; 92: 421\u2013425.","journal-title":"Acta Ophthalmol"},{"key":"BFeye2016126_CR3","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.ophtha.2005.01.042","volume":"112","author":"R van der Valk","year":"2005","unstructured":"van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH . Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005; 112: 1177\u20131185.","journal-title":"Ophthalmology"},{"key":"BFeye2016126_CR4","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701\u2013713.","journal-title":"Arch Ophthalmol"},{"key":"BFeye2016126_CR5","doi-asserted-by":"publisher","first-page":"945","DOI":"10.2147\/OPTH.S19999","volume":"5","author":"RD Fechtner","year":"2011","unstructured":"Fechtner RD, Harasymowycz P, Nixon DR, Vold SD, Zaman F, Williams JM et al. Twelve-week, randomized, multicenter study comparing a fixed combination of brimonidine-timolol with timolol as therapy adjunctive to latanoprost. Clin Ophthalmol 2011; 5: 945\u2013953.","journal-title":"Clin Ophthalmol"},{"key":"BFeye2016126_CR6","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1089\/jop.2012.0195","volume":"29","author":"AG Konstas","year":"2013","unstructured":"Konstas AG, Hollo G, Haidich AB, Mikropoulos DG, Giannopoulos T, Voudouragkaki IC et al. Comparison of 24-hour intraocular pressure reduction obtained with brinzolamide\/timolol or brimonidine\/timolol fixed-combination adjunctive to travoprost therapy. J Ocul Pharmacol Ther 2013; 29: 652\u2013657.","journal-title":"J Ocul Pharmacol Ther"},{"key":"BFeye2016126_CR7","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.2147\/OPTH.S25987","volume":"5","author":"K Lorenz","year":"2011","unstructured":"Lorenz K, Rosbach K, Matt A, Pfeiffer N . Addition of a fixed combination of brinzolamide 1%\/timolol 0.5% to prostaglandin monotherapy in patients with glaucoma or ocular hypertension. Clin Ophthalmol 2011; 5: 1745\u20131750.","journal-title":"Clin Ophthalmol"},{"key":"BFeye2016126_CR8","doi-asserted-by":"publisher","first-page":"853","DOI":"10.2147\/PPA.S53162","volume":"8","author":"QH Nguyen","year":"2014","unstructured":"Nguyen QH . Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus. Patient Prefer Adherence 2014; 8: 853\u2013864.","journal-title":"Patient Prefer Adherence"},{"key":"BFeye2016126_CR9","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1016\/j.ophtha.2014.06.022","volume":"121","author":"T Aung","year":"2014","unstructured":"Aung T, Laganovska G, Hernandez Paredes TJ, Branch JD, Tsorbatzoglou A, Goldberg I . Twice-daily brinzolamide\/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension. Ophthalmology 2014; 121: 2348\u20132355.","journal-title":"Ophthalmology"},{"key":"BFeye2016126_CR10","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s12325-014-0168-y","volume":"31","author":"SA Gandolfi","year":"2014","unstructured":"Gandolfi SA, Lim J, Sanseau AC, Parra Restrepo JC, Hamacher T . Randomized trial of brinzolamide\/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension. Adv Ther 2014; 31: 1213\u20131227.","journal-title":"Adv Ther"},{"key":"BFeye2016126_CR11","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1001\/jamaophthalmol.2013.188","volume":"131","author":"G Katz","year":"2013","unstructured":"Katz G, Dubiner H, Samples J, Vold S, Sall K . Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%. JAMA Ophthalmol 2013; 131: 724\u2013730.","journal-title":"JAMA Ophthalmol"},{"key":"BFeye2016126_CR12","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1089\/jop.2012.0235","volume":"29","author":"QH Nguyen","year":"2013","unstructured":"Nguyen QH, McMenemy MG, Realini T, Whitson JT, Goode SM . Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%\/brimonidine 0.2%. J Ocul Pharmacol Ther 2013; 29: 290\u2013297.","journal-title":"J Ocul Pharmacol Ther"},{"key":"BFeye2016126_CR13","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2147\/OPTH.S46881","volume":"7","author":"JT Whitson","year":"2013","unstructured":"Whitson JT, Realini T, Nguyen QH, McMenemy MG, Goode SM . Six-month results from a phase III randomized trial of fixed-combination brinzolamide 1%+brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertension. Clin Ophthalmol 2013; 7: 1053\u20131060.","journal-title":"Clin Ophthalmol"},{"key":"BFeye2016126_CR14","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.2147\/OPTH.S13884","volume":"4","author":"JK Schmier","year":"2010","unstructured":"Schmier JK, Lau EC, Covert DW . Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogs. Clin Ophthalmol 2010; 4: 1137\u20131143.","journal-title":"Clin Ophthalmol"},{"key":"BFeye2016126_CR15","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.jclinepi.2008.04.012","volume":"62","author":"R van der Valk","year":"2009","unstructured":"van der Valk R, Webers CA, Lumley T, Hendrikse F, Prins MH, Schouten JS . A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure. J Clin Epidemiol 2009; 62: 1279\u20131283.","journal-title":"J Clin Epidemiol"},{"key":"BFeye2016126_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/IJG.0b013e3181fc8142","volume":"21","author":"I Goldberg","year":"2012","unstructured":"Goldberg I, Crowston JG, Jasek MC, Stewart JA, Stewart WC, ADAPT Study Investigator Group. Intraocular pressure-lowering efficacy of brinzolamide when added to travoprost\/timolol fixed combination as adjunctive therapy. J Glaucoma 2012; 21: 55\u201359.","journal-title":"J Glaucoma"},{"key":"BFeye2016126_CR17","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M, Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120: 1268\u20131279.","journal-title":"Arch Ophthalmol"},{"key":"BFeye2016126_CR18","first-page":"741","volume":"4","author":"AJ Lee","year":"2010","unstructured":"Lee AJ, McCluskey P . Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension. Clin Ophthalmol 2010; 4: 741\u2013764.","journal-title":"Clin Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/eye2016126.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye2016126","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye2016126.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:27:35Z","timestamp":1684430855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/eye2016126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,1]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["BFeye2016126"],"URL":"https:\/\/doi.org\/10.1038\/eye.2016.126","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,1]]},"assertion":[{"value":"18 December 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RDF has received consultant fees from Alcon and Bausch & Lomb, and research support from Alcon and Allergan. JSM has received research funding from Alcon, Allergan, Glaukos, Inotek, and Merck; consultant fees from Aerie, Alcon, Allergan, Inotek, and Sucampo; and lecture fees from Alcon, Allergan, and Sucampo. DAH is an Alcon employee. DLB has received consultant fees from Alcon and Ivantis, and research support from the National Eye Institute, Glaucoma Research Foundation, Research to Prevent Blindness, and New World Medical, Inc. HBD has received speakers bureau fees from Alcon.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}